FDA delays PDUFA for Delcath's chemosaturation system

Delcath Systems Inc. (NASDAQ:DCTH) said FDA extended the PDUFA date by three months for an NDA for Melblez Kit chemosaturation system, which delivers melphalan to treat unresectable ocular melanoma th...